A reliable measure to predict peripheral blood progenitor cell (PBPC) autograft CD34 + cell content is required to optimize the timing of PBPC collection. We prospectively examined the peripheral blood (PB) CD34 
Rapid and durable hematopoietic recovery is required following intensive therapy and autologous peripheral blood progenitor cell transplantation (PBPCT). Although, no definitive assay for the pluripotent hematopoietic stem cell exists, 1 a number of surrogate laboratory measures are used to predict hematopoietic recovery following PBPC transplantation. 2 These include the autograft mononuclear cell count (MNC), clonogenic assays in semi-solid media, usually the colony-forming unit granulocyte-macrophage (CFU-GM), and more recently the number of hematopoietic cells marked by the progenitor cell antigen CD34. 3 Indeed, as the CD34 + cell content in the autograft correlates well with the rate of hematopoietic recovery, it is now assessed routinely at many centers with threshold values of 2-5 × 10 6 CD34 + cells/kg predicting rapid and durable engraftment following PBPCT. 4 However, obtaining PBPCs by leukapheresis is expensive and there is morbidity, albeit small, associated with the procedure. Consequently, a reliable assay to predict the CD34 + cell yield is required to optimize the timing of collections. To determine the optimal time of PBPC collection, we prospectively examined a number of parameters in the peripheral blood (PB) of patients on the day of planned leukapheresis, and correlated these with various parameters in the autograft product.
Methods
Immediately prior to 235 consecutive PBPC collection procedures, the PB white blood cell (WBC), MNC, platelet and CD34
+ cell counts were determined and correlated with various autograft parameters namely, CD34
+ cell, CFU-GM and MNC content. These autograft parameters were expressed as a function of patient body weight. CD34 + cells/kg in the autograft was also compared to the other autograft parameters.
Patient characteristics
All patients undergoing PBPC harvesting at our institute between June 1996 and June 1997 were included and their disease characteristics are summarized in Table 1 . This provided 235 complete data sets for analysis.
Apheresis procedure
The mobilization strategy employed various chemotherapeutic agents supplemented with rhGCSF (10 g/kg), or utilized rhGCSF (10 g/kg) alone (Table 2) . Following chemotherapy and cytokine mobilization, PBPC collection was initiated when the patient's PB WBC returned to Ͼ1.5 × 10 9 /l and/or the PB absolute neutrophil count (ANC) reached 1.0 × 10 9 /l following the nadir. A minimum platelet count of 30 × 10 9 /l was also required. For patients mobilized with cytokine alone, apheresis was commenced 5 days following initiation of G-CSF. By employing these standard trigger points for initiating apheresis, patients were harvested between 5-16 days following mobilization. During the study, the PB CD34 + cell count was not used as a criterion for initiating apheresis.
Apheresis was performed using a Haemonetics V50, CS3000plus (Baxter Healthcare Corp, Deerfield, IL, USA) or Spectra (Cobe, Denver, CO, USA) cell separators. Blood was collected via a central venous access device or from peripheral veins with 1.5-2.5 times the patient's estimated blood volume processed.
Cell counts
Following appropriate dilution with Isoton III (Coulter, Hialeah, FL USA), total WBC counts for PB and PBPC samples were determined on a Coulter STKS analyzer (Coulter). A 100 cell manual differential count was used to determine the ANC. The MNC count was calculated by subtracting the ANC from the total WBC count.
Colony assays
CFU-GM assays were performed by culture in Iscove's modified Dulbecco's medium (Gibco Laboratories, New York, USA) containing 3% agar, 15% fetal calf serum (FCS) supplemented with rhIL-6 (6.66 ng/ml), rhG-CSF (3.33 ng/ml), rhGM-CSF (1.33 ng/ml) and rhSCF (1.0 ng/ml). Cultures were plated in duplicate at 1 × 10 5 cells ml and incubated at 37°C for 14 days in a humidified environment with 5% CO 2 . Colonies containing more than 50 cells were scored. The CFU-GM content of the autograft was then calculated from the colonies scored per ml and the total cells/kg.
CD34 analysis
The PBPCs and their accompanying PB samples were analyzed for the percentage of CD34 + cells by bivariate flow cytometry using phycoerythrin-conjugated class III antibodies to the CD34 antigen (clone HPCA-2) and peridium chlorophyl protein (PerCP) conjugated anti-CD45 (all antibodies from Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), using an in-house whole blood lysis methodology which has been verified against the International Society of Hematotherapy and Graft Engineering (ISHAGE) guidelines. 5, 6 Briefly, 1 × 10 6 cells, either in whole blood or the apheresis collection product, were added to an aliquot of anti-CD34 PE and anti-CD45 PerCP which had previously been titrated to provide a saturating antibody concentration, and incubated for 20 min at room temperature. This was followed by addition of red cell lysing solution (FACS lysing solution, Becton Dickinson), followed by brief vortex mixing and incubation for 10 min at room temperature. The cells were washed once by adding imidazole buffered saline with 2% bovine serum and 0.1% Na azide and centrifuging at 600 g. Without delay they were analyzed on a Becton Dickinson FACSCalibur flow cytometer by acquiring florescence and forward light scatter data on 120 000 ungated events. Subsequent data analysis was performed on the listmode data files using Becton Dickinson Cellquest software v3.0 (Becton Dickinson). In all list mode data analysis 'true' CD34 + events were defined as having the dual characteristics of bright CD34 expression and low-to-intermediate CD45 expression (Figure 1 ). Using the autograft WBC count, %CD34
+ cells and the patient's actual body weight, CD34
+ cells/kg body weight was determined.
Statistical methods
A correlation matrix was used to determine all possible permutations of the available parameters and statistical analysis of correlation between the various measured and calculated parameters was performed using linear regression analysis. This included three separate sets of correlations; a correlation of the PB parameters to one another, correlation of the PB parameters to the PBPC parameters and correlation of the PBPC parameters with the overall PBPC yield (CD34 + cells/kg). Statistics were performed on StatXact 3 for windows (CYTEL Software, Cambridge, MA, USA) and S-PLUS version 3.3 for Windows (StatSci; MathSoft, Seattle, WA, USA).
Results
Two hundred and thirty-five consecutive apheresis procedures were performed. The median and mean number of procedures per patient was 4.0 (range: 2-10) ( + cells by bivariate flow cytometry using phycoerythrin (PE)-conjugated antibodies to the CD34 antigen and peridium chlorophyl protein (PerCP)-conjugated anti-CD45 using an in-house whole blood lysis methodology which has been verified against the ISHAGE guidelines. Cells were analyzed by acquiring florescence and forward light scatter data on 120 000 ungated events. In all list mode data analysis 'true' CD34 + events were defined as having the dual characteristics of bright CD34 expression and low to intermediate CD45 expression. This representative example demonstrates 0.95% CD34 + events.
The correlations between the various PB parameters are detailed in Table 3 . Not unexpectedly there were significant correlations between PB WBC and PB MNC (r = 0.8079; P Ͻ 0.005) and between PB % CD34 + cells and PB CD34
+ cells/l (r = 0.4167; P Ͻ 0.05). However, the correlation between PB CD34 + cell count and PB WBC (r = 0.2468), PB MNC (r = 0.2911) and PB platelet count (r = 0.0901) was poor.
The relationship between the PB and autograft parameters is detailed in Table 4 . There was a strong linear relationship between PB CD34 + cells/l and PBPC CD34 + cells/kg (r = 0.8477; P Ͻ 0.005). The PB CD34 + cells/l was less strongly related to the autograft % CD34
+ cells (r = 0.5767; P Ͻ 0.05), CFU-GM/kg (r = 0.5512; P Ͻ 0.05) and MNC/kg (r = 0.5001; P Ͻ 0.05). The peripheral blood % CD34
+ cells also showed a modest correlation with a number of PBPC autograft parameters; namely PBPC % CD34
+ cells (r = 0.5938; P Ͻ 0.05) and PBPC CD34
+ cells/kg (r = 0.4446; P = 0.06). Figure 2 demonstrates the corresponding regression plots for these correlations. Figure 2a , demonstrates the correlation of peripheral blood CD34+ cells/l and PBPC CD34
+ cells/kg harvested, these same data are also represented on a loglog scale in Figure 3 . The correlation between these two parameters is 0.8477 by linear regression (P Ͻ 0.005). These two parameters showed the strongest correlation of all parameters studied. We further performed multiparameter statistical analysis to examine the relationship between various PB parameters (PB CD34 + cells/l, % PB CD34 + cells, PB MNC, PB WCC and PB platelets) and PBPC CD34 + cell yield. By multivariate analysis, the PB CD34 + cells/l was the only independently significant predictor of autograft CD34
+ cell content (P Ͻ 0.005).
The correlation between autograft CD34
+ cells/kg and other PBPC autograft parameters is detailed in Table 5 . There was a significant correlation with PBPC CFU-GM/kg (r = 0.6429; P Ͻ 0.05).
On the basis of the significant correlation between peripheral blood CD34
+ cells/l and PBPC CD34 + cells/kg, we further examined this relationship to determine a threshold value for peripheral blood CD34 + cells that would predict a satisfactory harvest. In our institution a total autograft CD34 + cell content of 2 × 10 6 /kg CD34 + cells reliably predicts engraftment post-transplant. Consequently, we aim to obtain a minimum of 0.5 × 10 /kg, we demonstrate that a PB CD34 + cell count of Ͼ5.0 × 10 6 /l predicts for a satisfactory harvest (Figure 3) .
We next sought to re-examine the original data set and determine the incidence of false-negative and false-positive outcomes. False-negatives, ie a good collection (PBPC CD34 + cells Ͼ 0.5 × 10 
the PB CD34
+ cell threshold value of 5.0 × 10 6 /l favors the scenario of inadequate collections. However, we believe that this feature is of clinical relevance in that very few adequate collections are missed.
Discussion

Mobilization of PBPC into the circulation results in an increase in measurable CD34
+ cells. 2 Since this phenomenon is transient, the optimal timing of PBPC collection is critical to maximize the efficiency of the procedure. A number of criteria have previously been utilized to determine the time to initiate collection. These include the number of days post-mobilization, the PB WBC and the PB MNC. More recently, others have examined the role of the PB CD34 count as a predictor of autograft yield. [7] [8] [9] Here, we report the results of a comprehensive comparison of various PB and autograft parameters to determine the optimal strategy for maximizing PBPC yield.
We examined the correlation between the PB WBC, MNC, platelet and CD34 + cell count and the autograft MNC, CFU-GM and CD34 content. We were particularly interested in determining whether the peripheral blood CD34
+ cell count could reliably predict the autograft CD34 + cell yield. Indeed, there was a strong correlation between the PB CD34 + cells/l and the autograft CD34 + cells/kg (r = 0.8409; P Ͻ 0.005). There was also a significant, albeit weaker, correlation with autograft CFU-GM/kg. We also examined the WBC, MNC and platelet count in the PB as potential predictors of PBPC autograft yield, however, none was found to predict harvest outcome. Indeed, PB CD34 + cells/l was the only independently significant predictor of autograft CD34
+ cell content (P = 0.005) ( Table 4 ). Based on the significant correlation between the PB CD34 + cell count and the autograft CD34 + cell content, we attempted to determine a threshold PB CD34
+ cell value that would predict a satisfactory harvest (Figure 3) . In our institution a total autograft CD34 + cell content of 2 × 10 6 /l predicts for a PBPC yield of greater than 0.5 × 10 6 /kg. As the correlation is linear, a higher PB CD34 threshold would predict for a higher PBPC yield. A corollary of increasing the threshold is that fewer 'inadequate harvests' would be obtained, however, this is at the expense of missing some 'adequate' collections (see text). + cell threshold to reduce the incidence of inadequate collections and thus reduce the number of aphereses performed. However, the price of this strategy is one of inevitably missing days when adequate collections could be obtained.
Four recently published studies have examined the relationship between PB CD34
+ cell count and autograft CD34 + cell content. [7] [8] [9] [10] All but one of these studies demonstrated a clinically significant correlation between PB CD34 + cells/l and CD34 + cell content in the autograft. [7] [8] [9] A further small study demonstrates a correlation between PB CD34 + cell count and autograft CD34 + Thy-1 + cell content. 11 Remes et al 8 + cell count to initiate the PBPC collection. By utilizing this criterion, they biased their studies for patients with a good CD34 + cell count in the autograft product. Our analysis examines all consecutive patients at our institution who underwent PBPC mobilization and collection without using the PB CD34
+ cell count to initiate collection. Consequently, we examine a wider spectrum of PB CD34
+ cell counts. This may partly explain the lower threshold value we describe. Furthermore, it is well recognized that there is substantial variation in CD34 detection methodologies between institutions and this may also contribute to the discrepancy between our study and others. Importantly, we have previously verified our CD34
+ cell enumeration methodology with the ISHAGE guidelines. 5, 6 Consequently, our findings could potentially find wider applicability.
It could be argued that our study was biased because of our criteria to initiate a harvest based on the ANC and minimum platelet values. However, the multivariate analysis demonstrates that the PB CD34 + cells/l was the only independently significant predictor of autograft CD34
We conclude that PB CD34 + cell count performed on the morning of planned PBPC collection, is a reliable predictor of the success of PBPC collections. We demonstrate that a PB CD34
+ cell count of greater than 5.0 × 10 6 /l is predictive of a PBPC CD34 + cell yield of at least 0.5 × 10 6 /kg. As a consequence of this study we now initiate apheresis collections only when the peripheral blood CD34 + cell count exceeds this threshold.
